MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Abbott Laboratories

Отворен

СекторЗдравеопазване

128.67 -0.89

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

127.11

Максимум

130.1

Ключови измерители

By Trading Economics

Приходи

7.6B

9.2B

Продажби

339M

11B

P/E

Средно за сектора

17.001

57.333

EPS

1.09

Дивидентна доходност

1.8

Марж на печалбата

84.099

Служители

114,000

EBITDA

82M

3B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+11.42% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.80%

2.63%

Следваща дата на дивидент

15.05.2025 г.

Следваща дата на екс-дивидент

14.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3B

225B

Предишно отваряне

129.56

Предишно затваряне

128.67

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Abbott Laboratories Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.04.2025 г., 16:21 ч. UTC

Печалби

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16.04.2025 г., 12:14 ч. UTC

Печалби

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22.01.2025 г., 19:03 ч. UTC

Печалби

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22.01.2025 г., 18:20 ч. UTC

Печалби

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22.01.2025 г., 12:45 ч. UTC

Печалби

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16.04.2025 г., 15:09 ч. UTC

Пазарно говорене

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16.04.2025 г., 14:17 ч. UTC

Печалби

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16.04.2025 г., 11:34 ч. UTC

Печалби

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16.04.2025 г., 11:33 ч. UTC

Печалби

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16.04.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16.04.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16.04.2025 г., 11:31 ч. UTC

Печалби

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Reaffirms Full-Yr Guidance

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Sales $10.36B >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Net $1.33B >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q EPS 76c >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Adj EPS $1.09 >ABT

16.04.2025 г., 09:57 ч. UTC

Горещи акции

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1.02.2025 г., 18:14 ч. UTC

Топ новини

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22.01.2025 г., 16:40 ч. UTC

Топ новини
Печалби

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22.01.2025 г., 15:20 ч. UTC

Печалби

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22.01.2025 г., 15:08 ч. UTC

Печалби

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22.01.2025 г., 13:51 ч. UTC

Печалби

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22.01.2025 г., 13:39 ч. UTC

Топ новини
Печалби

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22.01.2025 г., 12:02 ч. UTC

Печалби

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22.01.2025 г., 12:01 ч. UTC

Печалби

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22.01.2025 г., 12:01 ч. UTC

Печалби

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q Net $9.23B >ABT

Сравнение с други в отрасъла

Ценова промяна

Abbott Laboratories Прогноза

Ценова цел

By TipRanks

11.42% нагоре

12-месечна прогноза

Среден 144.15 USD  11.42%

Висок 159 USD

Нисък 127 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Abbott Laboratories през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

18

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

128.52 / 129.7Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.